Subscribe to RSS
DOI: 10.1055/s-0042-1749414
Treatment of Acute Spinal Cord Injuries: A Survey Among Iberolatinoamerican Spine Surgeons – Part 1: Use of High-Dose Corticosteroids
Article in several languages: português | English Financial Support The present study received no financial support from public, commercial, or not-for-profit sources.
Abstract
Objective The aim of the present study was to evaluate the current practice of using of methylprednisolone sodium succinate (MPSS) in acute spinal cord Injuries (ASCIs) among spine surgeons from Iberolatinoamerican countries.
Methods A descriptive cross-sectional study design as a survey was conducted. A questionnaire composed of 2 sections, one on demographic data regarding the surgeons and MPSS administration, was sent by email to members of the Sociedad Ibero Latinoamericana de Columna (SILACO, in the Spanish acronym) and associated societies.
Results A total of 182 surgeons participated in the study: 65.4% (119) orthopedic surgeons and 24.6% (63) neurosurgeons. Sixty-nine (37.9%) used MPSS in the initial management of ASCIs. There were no significant differences between countries (p = 0.451), specialty (p = 0.352), or surgeon seniority (p = 0.652) for the use of corticosteroids in the initial management of ASCIs. Forty-five (65.2%) respondents reported using an initial high-dose bolus (30 mg/Kg) followed by a perfusion (5.4 mg/kg/h). Forty-six (66.7%) surgeons who used MPSS only prescribed it if the patients presented within 8 hours of the ASCI. Most of the surgeons (50.7% [35]) administered high-dose corticosteroids because of the conviction that it has clinal benefits and improves neurological recovery.
Conclusion Results from the present survey show that MPSS use in ASCI is not widespread within spine surgeons and that the controversy regarding its use remains unresolved. This is probably due to the low level of evidence of the available data, to variations over the years, to inconsistencies in acute care protocols, and to health service pathways.
The present work was developed at the Orthopedics Department of the Hospital and University Center of Porto, Porto, Portugal.
Publication History
Received: 04 January 2022
Accepted: 05 April 2022
Article published online:
02 August 2022
© 2022. Sociedade Brasileira de Ortopedia e Traumatologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
Referências
- 1 Fehlings MG, Tetreault LA, Wilson JR. et al. A Clinical Practice Guideline for the Management of Acute Spinal Cord Injury: Introduction, Rationale, and Scope. Global Spine J 2017; 7 (3, Suppl): 84S-94S
- 2 Shank CD, Walters BC, Hadley MN. Management of acute traumatic spinal cord injuries. Handb Clin Neurol 2017; 140: 275-298
- 3 Rabinstein AA. Traumatic Spinal Cord Injury. Continuum (Minneap Minn) 2018; 24 (2, Spinal Cord Disorders): 551-566
- 4 Fehlings MG, Wilson JR, Tetreault LA. et al. A Clinical Practice Guideline for the Management of Patients With Acute Spinal Cord Injury: Recommendations on the Use of Methylprednisolone Sodium Succinate. Global Spine J 2017; 7 (3, Suppl): 203S-211S
- 5 Shank CD, Walters BC, Hadley MN. Current Topics in the Management of Acute Traumatic Spinal Cord Injury. Neurocrit Care 2019; 30 (02) 261-271
- 6 Hurlbert RJ, Hadley MN, Walters BC. et al. Pharmacological therapy for acute spinal cord injury. Neurosurgery 2013; 72 (Suppl. 02) 93-105
- 7 Hadley MN, Walters BC, Grabb PA. et al. Pharmacological therapy after acute cervical spinal cord injury. Neurosurgery 2002; 50 (3, Suppl): S63-S72
- 8 Evaniew N, Noonan VK, Fallah N. et al; RHSCIR Network. Methylprednisolone for the Treatment of Patients with Acute Spinal Cord Injuries: A Propensity Score-Matched Cohort Study from a Canadian Multi-Center Spinal Cord Injury Registry. J Neurotrauma 2015; 32 (21) 1674-1683
- 9 Bracken MB, Shepard MJ, Collins WF. et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990; 322 (20) 1405-1411
- 10 Hurlbert RJ. Methylprednisolone for the treatment of acute spinal cord injury: point. Neurosurgery 2014; 61 (Suppl. 01) 32-35
- 11 Falavigna A, Quadros FW, Teles AR. et al. Worldwide Steroid Prescription for Acute Spinal Cord Injury. Global Spine J 2018; 8 (03) 303-310
- 12 Werndle MC, Zoumprouli A, Sedgwick P, Papadopoulos MC. Variability in the treatment of acute spinal cord injury in the United Kingdom: results of a national survey. J Neurotrauma 2012; 29 (05) 880-888
- 13 Felleiter P, Müller N, Schumann F, Felix O, Lierz P. Changes in the use of the methylprednisolone protocol for traumatic spinal cord injury in Switzerland. Spine (Phila Pa 1976) 2012; 37 (11) 953-956
- 14 Bracken MB, Shepard MJ, Holford TR. et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997; 277 (20) 1597-1604
- 15 Teles AR, Cabrera J, Riew KD, Falavigna A. Steroid Use for Acute Spinal Cord Injury in Latin America: A Potentially Dangerous Practice Guided by Fear of Lawsuit. World Neurosurg 2016; 88: 342-349